| Document |
Document Title |
|
WO/2022/196858A1 |
The present invention relates to a novel amino acid derivative, a preparation method therefor, and a pharmaceutical composition for treating hepatitis B or D, comprising same. A compound represented by chemical formula 1, according to th...
|
|
WO/2022/171101A1 |
The present application relates to a steroid conjugate, and in particular, to a compound or a tautomer, a mesomer, a racemate, an enantiomer, and a diastereoisomer thereof, or a mixture form thereof, or a pharmaceutically acceptable salt...
|
|
WO/2022/142385A1 |
The present invention provides a method for refining dienogest. The method is a recrystallization method. The present invention belongs to the technical field of medicine synthesis. The refining of dienogest comprises the following steps...
|
|
WO/2022/115381A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein ring D and the substituents are defined herein. Also provided are pharmaceutical compositions comprising a compound of Formula (I) or a p...
|
|
WO/2022/091136A1 |
The present disclosure provides a compound of Formula (I) and its polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The present disclosure also reveals ...
|
|
WO/2022/059948A1 |
The present invention relates to a method for mass-producing sodium taurodeoxycholate, wherein isopropyl alcohol is used in order to produce the sodium taurodeoxycholate commercially, and separation and purification are carried out using...
|
|
WO/2022/039983A2 |
Methods of making cholic acid derivatives, particularly ursodeoxycholic acid, tauroursodeoxycholic acid, 7-ketolithocholic acid, obeticholic acid, their carboxyl ate salts and carboxyl ate esters, and starting materials and intermediates...
|
|
WO/2022/022623A1 |
The present invention belongs to the technical field of medicine, and particularly relates to an arenobufagin derivative, a preparation method therefor, a pharmaceutical composition thereof, and the use thereof. The arenobufagin derivati...
|
|
WO/2022/006145A1 |
The present disclosure relates to compositions derived from bioreachable molecules, such as amino acids and/or steroids. In particular, the composition can be a monomer, a polymer, or a copolymer derived from an amino acid dimer. Such co...
|
|
WO/2021/262836A1 |
Provided herein is a compound of the Formula (I) or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3a, R4a, R4b, R5, R6, R7, R11a, R11b, R15a, R15b, R16,R17, R19, RX, RY, and t are defined herein. Also provided herein are...
|
|
WO/2021/252761A2 |
Disclosed herein are monomeric and oligomeric compound embodiments for use as contraceptive agents. Monomeric compound embodiments disclosed herein comprise substituents that facilitate the ability of the compounds to exhibit progestogen...
|
|
WO/2021/236953A1 |
Cationic steroidal antimicrobial (CSA) compounds having a structure of Formula I, II or III, or salt thereof, wherein at least one of R1-R18, (e.g., R18) includes a terpenyl group attached via an ester or amide linkage and at least one R...
|
|
WO/2021/213984A1 |
The present invention relates to a new synthesis of 7- dehydrocholesterol or itsOH-protected forms of the formula I by the reaction of a compound of formula (ll)in the presence of a solvent of formula (III), comprising the step (a) where...
|
|
WO/2021/214685A1 |
The present invention refers to a method for the preparation of a compound of formula (I).
|
|
WO/2021/213988A1 |
The present invention relates to the purification of 7-dehydrocholesterol or 25-hydroxy-7-dehydrocholesterol or their OH-protected forms, respectively. It has been found that the process using organic solvent nanofiltration allows an eff...
|
|
WO/2021/194298A1 |
The present invention relates to nanoparticles comprising drug dimers, and a use thereof. The nanoparticles comprising drug dimers, of the present invention, can increase drug content and improve the drug dispersibility. In addition, the...
|
|
WO/2021/184789A1 |
Disclosed in the present invention are an epristeride impurity, and a preparation method therefor and the use thereof, which fall within the field of medicinal chemistry. The chemical name of the epristeride impurity is 17β-(N-tert-buty...
|
|
WO/2021/188148A1 |
This disclosure provides crystalline polymorphs of squalamine phosphate, methods of making the same, and methods of treatment using the same.
|
|
WO/2021/188778A2 |
Provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R 4a, R4b, R5, R6a, R6b, R11a, R11b, R15a, R15b, R16a, R16b, R18, R19, R20a, R20b, X, A, Z, q, u, r, s, t, m, and n are de...
|
|
WO/2021/179513A1 |
The present invention relates to an influenza virus neuraminidase inhibitor, a preparation method therefor and an application thereof, which belong to the technical field of pharmaceutical chemistry. The structural general formula of the...
|
|
WO/2021/163273A1 |
The present invention relates generally to the use of a glucocorticoid receptor antagonist for treating cancer, specifically solid tumors and prostate cancer.
|
|
WO/2021/155167A1 |
GCPII inhibitors comprising 2-(phosphonomethyl) pentanedioic acid (2-PMPA) conjugated to a bile acid and their use for treating a disease or condition associated with elevated levels of GCPII, including inflammatory bowel disease.
|
|
WO/2021/142477A1 |
The invention of this disclosure is directed to a neuroactive steroid (NAS) of a novel structure. This invention is also directed to a pharmaceutical composition comprising the neuroactive steroid (NAS) and salts thereof. The pharmaceuti...
|
|
WO/2021/140480A1 |
It is provided a method for the preparation of 3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-carboxyl
ic acid comprising the step of: d) reacting compound (IV) with methane sulphonyl chloride to get methyl 7α,12α-diacetyloxy-3α-...
|
|
WO/2021/116935A1 |
The present invention relates to compounds of formula (I), to pharmaceutical compositions thereof and to their uses, in particular in the treatment and/or prevention of GPBAR1 mediated diseases.
|
|
WO/2021/100029A2 |
The present invention relates to Fulvestrant prodrugs and process for the preparation thereof. The present disclosure also relates to pharmaceutical composition of Fulvestrant prodrugs and method of treatment using the same.
|
|
WO/2021/069570A1 |
Compounds and compositions for the activation of SERCA2a are disclosed. In particular, provided are compounds that act as predominantly pure or pure SERCA2a activators while only moderately inhibiting the Na+/K+ ATPase. In general, the d...
|
|
WO/2021/025973A1 |
The present application relates generally to novel aminosterol compounds, compositions comprising the same, and methods of making and using the novel aminosterol compounds and compositions.
|
|
WO/2021/023100A1 |
Disclosed are deoxycholic acid compounds, pharmaceutical compositions thereof and the use thereof in the preparation of drugs for treating liver diseases. The structure of the deoxycholic acid compounds is as shown in formula I, or a pha...
|
|
WO/2021/025974A1 |
The present application relates generally to novel aminosterol compounds, compositions comprising the same, and methods of making and using the novel aminosterol compounds and compositions.
|
|
WO/2020/264512A1 |
Provided herein in part is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of Formula I, and methods of using the compounds, e.g, in the treatment of CNS- relate...
|
|
WO/2020/264495A1 |
Provided herein is a compound of Formula (1-I): or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R11a, R11b, R16a, R16b, R19, R18, X, q, r, s, t, u, and n are defined herein. Also provided here...
|
|
WO/2020/243488A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7a, R11a, R11b, R12a, R12b, R16a, R16b, R19, R11a, R22, RX, RY and n are defined he...
|
|
WO/2020/200335A1 |
The invention provides 3α5β–steroid compounds of general formula I. These compounds are useful in the treatment of epilepsy or comorbidities associated with epilepsy or conditions associated with convulsions, such as seizures associa...
|
|
WO/2020/187965A1 |
The invention relates to an efficient and industrially applicable process for the preparation and purification of allopregnanolone and intermediates thereof without the assistance of column chromatography.
|
|
WO/2020/182228A1 |
A method of refining sodium taurocholate is disclosed. The method comprises dissolving a crude sodium taurocholate product in an alcohol solvent, adding an ester solvent while hot, filtering after cooling, and drying under reduced pressu...
|
|
WO/2020/172289A1 |
Described are deuterated forms of aminosterols, or a pharmaceutically acceptable salt thereof, wherein one or more hydrogen atoms at one or more positions selected from Cl, C2, C3, C4, C5, C6, C7, C8, C9, C11, C12, C14, C15, C16, C17, C1...
|
|
WO/2020/168283A1 |
The present disclosure relates to methods of managing cancer by modulating/inhibiting cap methyltransferase enzyme. The modulation/inhibition is carried out by pharmacological or biological inhibitors, including but not limited to compou...
|
|
WO/2020/146541A2 |
Provided herein are compounds, compounds including traceless linkers, protein conjugates thereof, and compositions thereof. Also provided herein are methods for the treatment of diseases, disorders, and conditions, and/or the management ...
|
|
WO/2020/132504A1 |
Provided herein is a compound of Formula (I) or pharmaceutically acceptable salt thereof, wherein R2a, R2b, R4a, R4b, R6, R7, R11a, R11b, R16, R17, R3, R5, R19 and RX are defined herein and wherein RY represents optionally substituted he...
|
|
WO/2020/128514A1 |
2-Fluorinated bile acid compounds of general formula (I) wherein at least one of R1 and R2 represents F and the other is chosen 3 from H and F and wherein R3 is as defined herein; are of use in the treatment and prevention of neurodegene...
|
|
WO/2020/119836A1 |
A process for preparing obeticholic acid, wherein the 7-keto-litocholic acid amide of formula (II), where R1, R2 are a C1-C6 n-alkyl, or together a C5-C6 cycle and the protecting group on the hydroxyl in position 3 is a carbamoyl with th...
|
|
WO/2020/115371A1 |
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof (I) wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or ...
|
|
WO/2020/118060A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2 a, R2 b, R4 a, R4 b, R6a, R6b, R7a,R7b,R11a, R11b, R12a,R12b, R18, RD, and q are defined herein. L is selected...
|
|
WO/2020/084094A1 |
The present invention relates to a process for preparing a nitrated compound, comprising the step of reacting a compound (A) comprising at least one substituted or unsubstituted aromatic or heteroaromatic ring, wherein said heteroaromati...
|
|
WO/2020/053509A1 |
The invention relates to a family of analogue compounds of squalamine for their use as a drug, in particular for treating or for preventing mycobacterial infections, in particular tuberculosis. A further aim of the present invention is n...
|
|
WO/2020/025942A1 |
Compounds of general formula (I): wherein R2a, R2b, R3a, R3b, R5, Y and R7 are as defined herein are selective agonists at the FXR receptor and are useful for the treatment or prevention of diseases and conditions including nonalcoholic ...
|
|
WO/2020/020728A1 |
Disclosed are compounds of formula (I), wherein X, Y, Z are annular atoms comprised in a five-membered carbocyclic or heterocyclic ring, selected from the group consisting of CH, NH, N, O, S; saidcarbocyclic or heterocyclic ring being op...
|
|
WO/2019/232208A1 |
Disclosed are cationic lipids which are compounds of Formula I. Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly ca...
|
|
WO/2019/209850A1 |
Described herein is the chemical structure of neurosteroid derivative compounds, methods of synthesizing the derivatives, and their uses in treating disorders, including those of the central nervous system. These compounds are readily sy...
|
